The standard therapies for advanced stage of diabetic retinopathy (proliferative form, PDR) are represented by anti-VEGF therapy (aflibercept, ranibizumab) but a percentage of patients do not improve or respond to this therapy (Wallsh and Gallemore, 2021; Gurung et al., 2023). Here, VEGFA is linked to diabetic retinopathy.